Skadden is advising TTAM Research Institute in its definitive agreement to acquire substantially all the assets of 23andMe Holding Co. TTAM is a nonprofit public benefit corporation based in California and led by 23andMe co-founder and former CEO Anne Wojcicki. It will acquire the company’s Personal Genome Service and Research Services business lines and the Lemonaid Health business for a purchase price of $305 million.
The agreement is the result of a final round of bidding conducted according to procedures approved by the U.S. Bankruptcy Court for the Eastern District of Missouri.
The Skadden team is led by Joseph Larkin, Ron Meisler, Evan Hill, Richard West and Moshe Spinowitz.